CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 277 filers reported holding CRISPR THERAPEUTICS AG in Q2 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,848,586 | -30.6% | 216,977 | -14.1% | 0.02% | -45.5% |
| Q2 2023 | $14,187,252 | +18.4% | 252,712 | -4.6% | 0.04% | -10.2% |
| Q1 2023 | $11,982,241 | -10.7% | 264,918 | -19.7% | 0.05% | -7.5% |
| Q4 2022 | $13,411,817 | -12.1% | 329,934 | +41.3% | 0.05% | -31.2% |
| Q3 2022 | $15,256,000 | +1645.5% | 233,451 | +4223.2% | 0.08% | +2466.7% |
| Q2 2021 | $874,000 | -39.5% | 5,400 | -54.4% | 0.00% | -62.5% |
| Q1 2021 | $1,444,000 | +86.6% | 11,852 | +134.5% | 0.01% | +33.3% |
| Q4 2020 | $774,000 | +34.8% | 5,055 | -62.6% | 0.01% | -60.0% |
| Q1 2020 | $574,000 | -83.4% | 13,533 | -76.2% | 0.02% | -28.6% |
| Q4 2019 | $3,465,000 | +1058.9% | 56,885 | +796.1% | 0.02% | +600.0% |
| Q2 2019 | $299,000 | +43.1% | 6,348 | +8.4% | 0.00% | +50.0% |
| Q1 2019 | $209,000 | -64.0% | 5,854 | -71.2% | 0.00% | -71.4% |
| Q4 2018 | $581,000 | +60.5% | 20,350 | +157.0% | 0.01% | +16.7% |
| Q1 2018 | $362,000 | – | 7,919 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |